Pasireotide

Pasireotide

Clinical data
Trade names	Signifor
License data	EU EMA: Signifor
Routes of administration	Subcutaneous
ATC code	H01CB05 (WHO)
Legal status
Legal status	℞ (Prescription only)
Identifiers
IUPAC name [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate
Synonyms	SOM230
CAS Number	396091-73-9 Y
PubChem (CID)	9941444
IUPHAR/BPS	2018
DrugBank	DB06663 N
ChemSpider	8117062 N
UNII	98H1T17066 Y
KEGG	D10147 N
ChEBI	CHEBI:72312 N
ECHA InfoCard	100.211.883
Chemical and physical data
Formula	C58H66N10O9
Molar mass	1047.21 g/mol[1]
3D model (Jmol)	Interactive image
SMILES C1[C@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
InChI InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1 N Key:VMZMNAABQBOLAK-DBILLSOUSA-N N
NY (what is this?)  (verify)

Pasireotide (SOM230, trade name Signifor^[2]) is an orphan drug approved in the United States^[3] and Europe^[4] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.^[5][6] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

Pasireotide was approved for Cushing's disease by the EMEA in October 2009^[7] and by the FDA in December 2012.^[8]

Pasireotide LAR was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMEA one month earlier.^[9]

References